78 related articles for article (PubMed ID: 8465424)
1. Prophylactic OKT3: practical considerations for the prevention of first-dose reactions.
Doutrelepont JM; Abramowicz D; Borre B; Lemoine A; De Pauw L; Kinnaert P; Vereerstraeten P; Vanherweghem JL; Goldman M
Transplant Proc; 1993 Apr; 25(2 Suppl 1):45-6. PubMed ID: 8465424
[No Abstract] [Full Text] [Related]
2. Encephalopathy following the use of OKT3 in renal allograft transplantation.
Shihab FS; Barry JM; Norman DJ
Transplant Proc; 1993 Apr; 25(2 Suppl 1):31-4. PubMed ID: 8465419
[No Abstract] [Full Text] [Related]
3. Cytokine-release syndrome: differences between high and low doses of OKT3.
Norman DJ; Kimball JA; Barry JM
Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
[No Abstract] [Full Text] [Related]
4. Pentoxifylline reduces the first-dose reactions following OKT3.
Vincenti FG; Vasconcelos M; Birnbaum JL; Tomlanovich SJ; Amend WJ; Melzer JS; Snyder JP
Transplant Proc; 1993 Apr; 25(2 Suppl 1):57-9. PubMed ID: 8465428
[No Abstract] [Full Text] [Related]
5. Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients.
Leimenstoll G; Zabel P; Schroeder P; Schlaak M; Niedermayer W
Transplant Proc; 1993 Feb; 25(1 Pt 1):561-3. PubMed ID: 8438414
[No Abstract] [Full Text] [Related]
6. Tumor necrosis factor and interleukin-6 in cerebrospinal fluid of a patient with recurrent adverse central nervous system events following OKT3.
Agarwal RK; Ostaszewski ML; Feld LG; Springate JE; Moxey-Mims MM; O'Neil KM
Transplant Proc; 1993 Apr; 25(2):2143-4. PubMed ID: 8470295
[No Abstract] [Full Text] [Related]
7. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi K; Munn SR; Sterioff S
Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
[No Abstract] [Full Text] [Related]
8. Low-dose OKT3 induction therapy following renal transplantation leads to improved graft function and decreased adverse effects.
Brown M; Korb S; Light JA; Light T; Jonsson J; Aquino A
Transplant Proc; 1993 Feb; 25(1 Pt 1):553-5. PubMed ID: 8438411
[No Abstract] [Full Text] [Related]
9. Increased levels of sTNF receptors following OKT3 treatment.
Bemelman FJ; Jansen J; van der Poll T; Hack CE; van Deventer SJ; ten Berge RJ
Transplant Proc; 1994 Dec; 26(6):3094-5. PubMed ID: 7998082
[No Abstract] [Full Text] [Related]
10. Induction of an acute phase response after OKT3 therapy.
Pohanka E; Kovarik J; Klauser R; Woloszcsuk W; Zlabinger GJ
Transplant Proc; 1992 Feb; 24(1):269-70. PubMed ID: 1371618
[No Abstract] [Full Text] [Related]
11. Activation of coagulation and fibrinolysis during treatment with OKT3.
ten Berge RJ; Raasveld MH; van Diepen FN; Hack CE
Transplant Proc; 1993 Feb; 25(1 Pt 1):566-7. PubMed ID: 8438416
[No Abstract] [Full Text] [Related]
12. Morbidity of intraoperative OKT3 administration in primary cadaveric renal transplant recipients.
Kupin W; Venkat KK; Ikemiyashiro D; Ocdol H; Mozes M; Anaise D; Johnson C
Transplant Proc; 1993 Feb; 25(1 Pt 1):572-4. PubMed ID: 8438419
[No Abstract] [Full Text] [Related]
13. Administration of OKT3 in the operating room.
Robinson ST
Transplant Proc; 1993 Apr; 25(2 Suppl 1):41-2. PubMed ID: 8465422
[No Abstract] [Full Text] [Related]
14. Incidence and type of cancer following the use of OKT3: a single center experience with 557 organ transplants.
Batiuk TD; Barry JM; Bennett WM; Meyer MM; Tolzman D; Norman DJ
Transplant Proc; 1993 Feb; 25(1 Pt 2):1391. PubMed ID: 8382860
[No Abstract] [Full Text] [Related]
15. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3.
Sasaki AW; Lee RG; Porayko MK; Benner KG; Hennell KR; Wheeler LJ; Pinson CW
Transplantation; 1993 Jan; 55(1):216-9. PubMed ID: 8420054
[No Abstract] [Full Text] [Related]
16. Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients.
Fukuuchi F; Lefrançois N; Chapuis F; Gebuhrer L; Bosshard S; Dubernard JM; Touraine JL
Transplant Proc; 1996 Oct; 28(5):2808-9. PubMed ID: 8908070
[No Abstract] [Full Text] [Related]
17. Reduction of the initial febrile response to OKT3 with indomethacin.
First MR; Schroeder TJ; Hariharan S; Weiskittel P
Transplant Proc; 1993 Apr; 25(2 Suppl 1):52-4. PubMed ID: 8465426
[No Abstract] [Full Text] [Related]
18. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL
Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
[TBL] [Abstract][Full Text] [Related]
19. Nursing guidelines for muromonab-CD3 (OKT3).
Duffy MM; Nestor A
ANNA J; 1992 Oct; 19(5):493-5. PubMed ID: 1456797
[TBL] [Abstract][Full Text] [Related]
20. Brequinar sodium significantly reduces the incidence of steroid-resistant rejection and resource utilization in primary renal transplant patients compared with azathioprine.
Dunn JF; Hatch J; Precht A; Hart M; Li S
Transplant Proc; 1996 Apr; 28(2):955-7. PubMed ID: 8623479
[No Abstract] [Full Text] [Related]
[Next] [New Search]
